Israeli pharma company Teva Pharmaceuticals has launched a generic version of Delzicol (mesalamine) 400mg delayed-release capsules in the US.
Mesalamine Delayed-Release capsules are an aminosalicylate, approved for the treatment of mild to moderate ulcerative colitis in patients aged five years and above, and also for maintenance of remission of ulcerative colitis in adult patients.
Brendan O’Grady – Teva EVP and Head of North America Commercial said: “Ulcerative colitis is a chronic inflammatory bowel disease and we’re proud to provide another treatment option for patients.”
With the Mesalamine delayed-release capsules, Teva adds another drug for the treatment of gastrointestinal disorders to its portfolio. Teva’s portfolio includes close to 500 generic medicines which are approved by the FDA.
According to IMS data, as of February 2019, Delzicol delayed-release capsules had annual sales of nearly $130 million in the US.